Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
US-9643983-B2 · May 9, 2017 · US
This page is not indexed by search engines while we improve data quality.
Bhalay Gurdip — Human Necessities
Bhalay Gurdip holds 3 patents in Human Necessities, with representative filings summarized below.
| Metric | Value |
|---|---|
| Company | Bhalay Gurdip |
| Technology | Human Necessities |
| Patents in slice | 3 |
| Recent patents in slice | 0 |
| First year | 2015 |
| Last year | 2017 |
Representative patents
Notable publications linking Bhalay Gurdip to Human Necessities.
Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
US-9643983-B2 · May 9, 2017 · US
Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
US-9643983-B2 · May 9, 2017 · US
Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
US-9643983-B2 · May 9, 2017 · US
Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
US-9643983-B2 · May 9, 2017 · US
Recent filings
Latest patents from Bhalay Gurdip in Human Necessities.
Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
US-9643983-B2 · May 9, 2017 · US
Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
US-9643983-B2 · May 9, 2017 · US
Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
US-9643983-B2 · May 9, 2017 · US
Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
US-9643983-B2 · May 9, 2017 · US
Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
US-9643983-B2 · May 9, 2017 · US
Related pages
Navigate to parent entity pages.